UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/083,707	02/26/2002	Gregory G. Brucker	15305.32USU1	1518
23552 7590 12/28/2007 MERCHANT & GOULD PC P.O. BOX 2903			EXAMINER	
			TYSON, MELANIE RUANO	
MINNEAPOLI	LIS, MN 55402-0903		ART UNIT	PAPER NUMBER
			3773	
			MAIL DATE	DELIVERY MODE
			12/28/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

•	Application No.	Applicant(s)			
	10/083,707	BRUCKER ET AL.			
Office Action Summary	Examiner	Art Unit			
•	Melanie Tyson	3773			
The MAILING DATE of this communication					
Period for Reply	•	•			
A SHORTENED STATUTORY PERIOD FOR REI WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication If NO period for reply is specified above, the maximum statutory peri - Failure to reply within the set or extended period for reply will, by sta Any reply received by the Office later than three months after the may earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNI 1.1.136(a). In no event, however, may a iod will apply and will expire SIX (6) MO tute, cause the application to become A	ICATION. reply be timely filed NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 31	1 October 2007.				
2a) ☐ This action is FINAL. 2b) ☒ T	☐ This action is FINAL . 2b) ☑ This action is non-final.				
3) Since this application is in condition for allow	•	•			
closed in accordance with the practice unde	er <i>Ex parte Quayle</i> , 1935 C.I	D. 11, 453 O.G. 213.			
Disposition of Claims					
4) ⊠ Claim(s) 17,19 and 39-62 is/are pending in 4a) Of the above claim(s) is/are without 5) □ Claim(s) is/are allowed. 6) ⊠ Claim(s) 17,19, and 39-62 is/are rejected. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and	Irawn from consideration.				
Application Papers					
9) The specification is objected to by the Exam 10) The drawing(s) filed on is/are: a) a Applicant may not request that any objection to t Replacement drawing sheet(s) including the corr 11) The oath or declaration is objected to by the	accepted or b) objected to he drawing(s) be held in abeya rection is required if the drawing	nce. See 37 CFR 1.85(a). g(s) is objected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for fore a) All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the p application from the International Bure * See the attached detailed Office action for a least	ents have been received. ents have been received in A riority documents have beer eau (PCT Rule 17.2(a)).	Application No n received in this National Stage			
Attachment(s)					
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 	Paper No	Summary (PTO-413) (s)/Mail Date Informal Patent Application 			

10/083,707 Art Unit: 3773

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 31 October 2007 has been entered.

Response to Arguments

2. Applicant's arguments with respect to claims 17, 19, and 39-62 have been considered but are most in view of the new ground(s) of rejection.

Claim Objections

3. Claim 56 is objected to because of the following informalities: claim 56 contains a typographical error. Remove the term "a" from line 1. Appropriate correction is required.

Claim Rejections - 35 USC § 103

- 4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

10/083,707 Art Unit: 3773

- 5. The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:
 - 1. Determining the scope and contents of the prior art.
 - 2. Ascertaining the differences between the prior art and the claims at issue.
 - 3. Resolving the level of ordinary skill in the pertinent art.
 - 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 6. Claims 17, 19, 39, 40, 46, 57, 58 and 61 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lam (5,607,444) in view of Vardi et al. (6,325,826).

Lam discloses a system (see entire document) comprising only a single catheter having only a single balloon (for example, see Figures 1 and 6), and a bifurcation stent (for example, see Figures 2 and 3) including a stent body (20) and a plurality of movable members (25) engaged to the stent wall, retained substantially within the plane of the stent wall, and expandable radially outward from the stent wall to form a scaffold. Lam further discloses the movable members and stent body may be balloon expandable or self-expandable, and the bifurcation stent may be a hybrid stent such that a portion may be self-expandable while the other portion is balloon expandable, wherein both portions may be expanded simultaneously (for example, see column 7, line 20 - column 8, line 16). Lam fails to disclose the scaffold defines a side opening in the stent wall.

Vardi discloses a system (see entire document) comprising a bifurcation stent including a stent body and a plurality of movable members that extends radially outward from the stent wall to form a scaffold (for example, see Figure 8). Vardi teaches the scaffold defines a side opening in the stent wall, such that a portion of the movable

10/083,707 Art Unit: 3773

members expand towards a proximal end of the stent body and a portion of the movable members expand towards a distal end of the stent body (for example, see Figure 8). It is well within the general knowledge of one having ordinary skill in the art to apply a known technique to a known device to yield predictable results. Therefore, it would have been obvious to one having ordinary skill in the art at the time the invention was made to provide the movable members on a side wall, such that they radially expand to from a scaffold defining a side opening in the stent wall as taught by Vardi. Doing so would provide the stent the ability to be positioned across the bifurcation with the side opening positioned over the bifurcation point.

7. Claims 41-45, 47-56, 59, 60, and 62 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lam (5,607,444) in view of Vardi et al. (6,325,826), and further in view of Crocker et al. (5,843,116).

Lam in view of Vardi discloses a device as described above (see above for similar elements of claims 47-56 and 62), and further discloses a bulge region protruding radially outward from the body region when expanded to aid in expanding the movable members, the bulge region being positioned at a location between a proximal and distal end of the body, wherein in the unexpanded state the movable members are positioned over the bulge (for example, see Figures 1 and 6). However, Lam in view of Vardi fails to disclose the bulge is positioned at a predetermined circumferential location. Lam in view of Vardi discloses expansion and deformation of the stent can be accomplished through the use of various sized and shaped balloons (for example, see column 7, lines 20-23).

entire circumference of the body portion).

10/083,707 Art Unit: 3773

Crocker discloses a system (see entire document) comprising a catheter having a balloon (for example, see Figures 1-3). Crocker teaches a bulge region (30) being located between a proximal end and a distal end, wherein the bulge is positioned at a predetermined circumferential location (for example, see column 1, lines 10-15). Crocker further teaches the expansion characteristics can be achieved by modifying the expansion properties of the balloon itself, including providing zones of differing wall thickness (for example, see column 5, lines 40-45). It is well within the general knowledge of one having ordinary skill in the art to apply a known technique to a known device to yield predictable results. Therefore, it would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the balloon of Lam in view of Vardi as taught by Crocker. Doing so would provide higher expansive energy only where needed, such as along the center where the movable members lie across the bifurcation point, thus minimizing the risk of damaging surrounding tissue. With further respect to claims 59 and 62, it would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the bulge portion such that it extends around less than an entire circumference, since such a change would simply involve changing the shape of the bulge portion (for example, by varying the thickness of the balloon to accomplish a certain shape), and changing shapes and merely involves routine skill in the art (for example, see Bramfitt's patent 5,935,135; discloses bulge portions 28b or 28d in Figures 7B and 7D, which extend around less than an

10/083,707 Art Unit: 3773

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Melanie Tyson whose telephone number is (571) 272-9062. The examiner can normally be reached on Monday through Thursday 8:30-7 (max flex).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jackie Ho can be reached on (571) 272-4696. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Melanie Tyson Mol December 19, 2007 (JACKIE) TAN-UYEN HO SUPERVISORY PATENT EXAMINER